Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at two dose levels: 2060 ug and 3090 ug against Aflibercept.
Epistemonikos ID: 9998efa5ba50215e4ca1cc1ccf0299a96efc2d82
First added on: May 13, 2024